BioCryst Investor Relations
BioCryst Pharmaceuticals
2190 Parkway Lake Drive
Birmingham, Alabama 35244
Phone (205) 444-4600
Fax (205) 444-4640
info@biocryst.com
Financial Profile
NASD: (BCRX)
Sector: Healthcare
Industry: Biotechnology & Drugs
2190
Parkway Lake Drive
Birmingham, AL 35244
Phone: 1-205-444-4600
Fax: 1-205-444-4640
Employees: 106
Market Cap (Mil) $ : 111.585
Complete Financials: Mar 2008
Updated: 05/08/2008
BRIEF: For the fiscal year ended 31 December 2007, BioCryst Pharmaceuticals, Inc.'s revenues totaled $71.2M, up from $6.2M. Net loss decreased 33% to $29.1M. Revenues reflect increased income from collaborative & other research & development due to higher revenue from HHS related to contract for the development of peramivir. Lower loss also reflects improved operating margin. BioCryst Pharmaceuticals Inc. is a biotechnology company.
Officers:
Jon Stonehouse, President, Chief Executive Officer, Director
Stuart Grant, Chief Financial Officer, Senior Vice President
J. Claude Bennett, Chief Operating Officer, Director
Michael Darwin, Vice President - Finance, Principal Accounting Officer, Treasurer
David McCullough, Vice President - Strategic Planning and Commercialization
Thomas Simon, Interim Chief Medical Officer
TRANSFER AGENT: American Stock Transfer & Trust Co.
Company reincorporated in DE.
Key Ratios & Statistics
| Price & Volume | |
|---|---|
| Recent Price | $ 2.93 |
| 52 Week High | $ 13.18 |
| 52 Week Low | $ 2.75 |
| Avg Daily Vol (Mil) | 3.435 |
| Beta | 0.92 |
| Share Related Items | |
|---|---|
| Mkt. Cap. (Mil) | $ 111.585 |
| Shares Out (Mil) | 38.084 |
| Float (Mil) | 33.600 |
| Dividend Information | |
|---|---|
| Yield | N/A |
| Annual Dividend | 0.00 |
| Payout Ratio (TTM) | 0.00% |
| Financial Strength | |
|---|---|
| Quick Ratio (MRQ) | 3.26 |
| Current Ratio (MRQ) | 3.26 |
| LT Debt/Equity (MRQ) | 0.00 |
| Total Debt/Equity (MRQ) | 0.00 |
| Valuation Ratios | |
|---|---|
| Price/Earnings (TTM) | N/A |
| Price/Sales (TTM) | 1.53 |
| Price/Book (MRQ) | 1.84 |
| Price/Cash Flow (TTM) | N/A |
| Per Share Data | |
|---|---|
| Earnings (TTM) | $-.97 |
| Sales (TTM) | $2.17 |
| Book Value (MRQ) | $1.71 |
| Cash Flow (TTM) | $-.86 |
| Cash (MRQ) | $1.34 |
| Mgmt Effectiveness | |
|---|---|
| Return on Equity (TTM) | -33.72 |
| Return on Assets (TTM) | -27.51 |
| Return on Investment (TTM) | -33.72 |
| Profitability | |
|---|---|
| Gross Margin (TTM) | -36.94% |
| Operating Margin (TTM) | -50.64% |
| Profit Margin (TTM) | -45.75% |
Mil = Millions TTM = Trailing Twelve Months MRQ = Most Recent Quarter
Asterisk (*) indicates numbers are derived from Earnings Announcements
Pricing and volume data as of 05/08/2008